• Explore /
  • Poster
  • / SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab vs pembrolizumab alone for first-line treatment of BRAF V600E–mutant microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC).

SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab vs pembrolizumab alone for first-line treatment of BRAF V600E–mutant microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC).

Abstract Poster

Authors

null

Scott Kopetz

MD Anderson Cancer Center, Houston, TX;

Scott Kopetz , Tanios S. Bekaii-Saab , Takayuki Yoshino , Chin-Hee Chung , Xiaosong Zhang , Josep Tabernero

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05217446

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS268)

DOI

10.1200/JCO.2023.41.4_suppl.TPS268

Abstract #

TPS268

Poster Bd #

P10

Abstract Disclosures

Similar Posters

First Author: Scott Kopetz

First Author: Chetan Vakkalagadda

First Author: Yuki Matsubara

First Author: Haley Ellis